A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Trial Profile

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Loncastuximab tesirine (Primary)
  • Indications B cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Sponsors ADC Therapeutics
  • Most Recent Events

    • 12 Dec 2017 Interim analysis results (n=23; as of 23 Jun 2017) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 11 Dec 2017 Results published in the ADC Therapeutics media release.
    • 11 Dec 2017 According to an ADC Therapeutics media release, interim results of the trial were presented at the American Society of Hematology (ASH) Annual Meeting in Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top